|
|
|
Year :2022
|
Month :
October
|
Volume :
10
|
Issue :
4
|
Page :
PO01 - PO05
|
Probiotics (Bacillus clausii) for Prevention of Late-onset Sepsis in Preterm Infants (<34 weeks): A Randomised Controlled Trial
|
|
|
Correspondence Address :
P Namratha, Chinmayi R Joshi, Shailesh S Patil, Vijaykumar B Murteli,
Dr. Chinmayi R Joshi,
25, “Shri Ganesh”, Cariappa Colony, Nanawadi Road, Belagavi-590009, Karnataka, India.
E-mail: crjoshi58@rediffmail.com
|
|
Introduction: Late-Onset Sepsis (LOS) causes significant morbidity and mortality in preterm infants. Probiotics have been suggested to improve the integrity of mucosal barrier by modifying the enteric microflora and suppress the overgrowth and translocation of pathogens in the gut, thus preventing life-threatening infections. Although probiotics have a definite role in prevention of Necrotising Enterocolitis (NEC) in preterm neonates, their effect on prevention of LOS in preterm neonates is still uncertain.
Aim: To evaluate the role of probiotics in reducing incidence of LOS in preterm neonates (<34 weeks).
Materials and Methods: A double blinded randomised control trial was conducted in a tertiary care Neonatal Intensive Care Unit (NICU) in Karnataka, India between 1st January 2019 to 31st December 2019. Seventy haemodynamically stable preterm neonates, <34 weeks of Gestational Age (GA), were randomised into ‘Probiotic’ and ‘Placebo’ group. The probiotic group (n=36) was prophylactically administered Bacillus clausii suspension at a dose of 2.5 mL per oral (0.4×109 spores in 1 mL) BD with breast milk, from initiation of enteral feeds till seven days, discharge/ death/LOS, whichever was earlier. The placebo group (n=34) received breast milk with sterile water 2.5 mL per oral BD. All the neonates were investigated and managed as per standard hospital protocol. Primary outcome of the study was to find the incidence of LOS. Student’s t-test, Mann-Whitney U test, Chi-square test and Fisher’s-exact test were used for statistical analysis.
Results: There was no significant difference between the probiotic vs placebo group, with respect to incidence of LOS {(11.11% vs 17.7%); p-value >0.05} and duration of hospital stay {(10.86±3.19 vs 11.23±2.98 days); p-value >0.05}. However, incidence of feed intolerance in the probiotic group (11.11%) was significantly less than that the other (26.47%) (p<0.05).
Conclusion: Probiotics, prophylactically fed enterally, did not reduce the incidence of LOS but provide a promising strategy to prevent feed intolerance in premature neonates.
|
|
|
[
FULL TEXT ] | [
 ]
|
|
|
|
|